Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc A Pfeffer

Showing results (141-150 of 520) with videos related to

Pageof 52
Sort By:
Clinical Trials (London, England)|April 1, 2025
Response to Cleland and AnzarJanet Wittes, David L DeMets, KyungMann Kim, et al.
Clinical Trials (London, England)|April 1, 2025
Aspirin in primary prevention: Undue reliance on an uninformative trial led to misinformed clinical guidelinesJanet Wittes, David L DeMets, KyungMann Kim, et al.
Circulation|June 26, 2002
Omapatrilat reduces pulse pressure and proximal aortic stiffness in patients with systolic hypertension: results of the conduit hemodynamics of omapatrilat international research studyGary F Mitchell, Joseph L Izzo, Yves Lacourcière, et al.
American Heart Journal|June 7, 2011
Incremental value of echocardiographic assessment beyond clinical evaluation for prediction of death and development of heart failure after high-risk myocardial infarctionAnil Verma, Marc A Pfeffer, Hicham Skali, et al.
The American Journal of Cardiology|September 5, 2006
Evaluation of the National Cholesterol Education Program Adult Treatment Panel III algorithm for selecting candidates for statin therapy: insights from the A to Z trialJames A de Lemos, Stephen D Wiviott, Sabina A Murphy, et al.
Journal of the American College of Cardiology|May 16, 2006
Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programLars G Olsson, Karl Swedberg, Anique Ducharme, et al.
Circulation. Cardiovascular Quality and Outcomes|March 18, 2010
Cognitive function and anticoagulation control in patients with atrial fibrillationGreg C Flaker, Janice Pogue, Salim Yusuf, et al.
Lancet (London, England)|December 13, 2005
Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trialBradi B Granger, Karl Swedberg, Inger Ekman, et al.
European Journal of Heart Failure|September 6, 2017
Prevalence and prognostic importance of precipitating factors leading to heart failure hospitalization: recurrent hospitalizations and mortalityElke Platz, Pardeep S Jhund, Brian L Claggett, et al.
Journal of Cardiac Failure|March 14, 2013
Acute effects of withdrawal of cardiac resynchronization therapy on left and right ventricular function, dyssynchrony, and contractile function in patients with New York Heart Association functional class I/II heart failure: MADIT-CRTDorit Knappe, Anne-Catherine Pouleur, Amil M Shah, et al.
Pageof 52

Showing results (141-150 of 520) with videos related to

Sort By:
Pageof 52
Clinical Trials (London, England)|April 1, 2025
Response to Cleland and AnzarJanet Wittes, David L DeMets, KyungMann Kim, et al.
Clinical Trials (London, England)|April 1, 2025
Aspirin in primary prevention: Undue reliance on an uninformative trial led to misinformed clinical guidelinesJanet Wittes, David L DeMets, KyungMann Kim, et al.
Circulation|June 26, 2002
Omapatrilat reduces pulse pressure and proximal aortic stiffness in patients with systolic hypertension: results of the conduit hemodynamics of omapatrilat international research studyGary F Mitchell, Joseph L Izzo, Yves Lacourcière, et al.
American Heart Journal|June 7, 2011
Incremental value of echocardiographic assessment beyond clinical evaluation for prediction of death and development of heart failure after high-risk myocardial infarctionAnil Verma, Marc A Pfeffer, Hicham Skali, et al.
The American Journal of Cardiology|September 5, 2006
Evaluation of the National Cholesterol Education Program Adult Treatment Panel III algorithm for selecting candidates for statin therapy: insights from the A to Z trialJames A de Lemos, Stephen D Wiviott, Sabina A Murphy, et al.
Journal of the American College of Cardiology|May 16, 2006
Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programLars G Olsson, Karl Swedberg, Anique Ducharme, et al.
Circulation. Cardiovascular Quality and Outcomes|March 18, 2010
Cognitive function and anticoagulation control in patients with atrial fibrillationGreg C Flaker, Janice Pogue, Salim Yusuf, et al.
Lancet (London, England)|December 13, 2005
Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trialBradi B Granger, Karl Swedberg, Inger Ekman, et al.
European Journal of Heart Failure|September 6, 2017
Prevalence and prognostic importance of precipitating factors leading to heart failure hospitalization: recurrent hospitalizations and mortalityElke Platz, Pardeep S Jhund, Brian L Claggett, et al.
Journal of Cardiac Failure|March 14, 2013
Acute effects of withdrawal of cardiac resynchronization therapy on left and right ventricular function, dyssynchrony, and contractile function in patients with New York Heart Association functional class I/II heart failure: MADIT-CRTDorit Knappe, Anne-Catherine Pouleur, Amil M Shah, et al.
Pageof 52